

**Commissioner for the Department for Medicaid Services
Selections for Preferred Products**

This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner for the Department for Medicaid Services based on the July 16, 2015 Pharmacy and Therapeutics (P&T) Advisory Committee Meeting.

Description of Recommendation	Final Decision (s)
<p><u>New Products to Market: Cresemba[®]</u> Place this product non preferred in the PDL class titled Oral Antifungals.</p>	<p>Cresemba[®] will be placed non preferred in the PDL class titled Oral Antifungals.</p>
<p><u>New Products to Market: Namzaric[®]</u> Place this product non preferred in the PDL class titled Alzheimer's Agents.</p>	<p>Namzaric[®] will be placed non preferred in the PDL class titled Alzheimer's Agents.</p>
<p><u>New Products to Market: Corlanor[®]</u> Ivabradine (Corlanor[®]) will be approved if ALL of the following criteria are met:</p> <ul style="list-style-type: none"> • Diagnosis of chronic heart failure that is symptomatic; AND • Documentation of LVEF \leq 35 percent; AND • Patient is in sinus rhythm; AND • Documentation of resting heart rate \geq 70 bpm; AND • Patient is receiving maximally-tolerated doses of either bisoprolol, carvedilol, or metoprolol succinate extended release as verified by claims history. If no history of claims for a beta blocker, documentation of reason for contraindication to beta blocker therapy is required. 	<p>Ivabradine (Corlanor[®]) will be approved if ALL of the following criteria are met:</p> <ul style="list-style-type: none"> • Diagnosis of chronic heart failure that is symptomatic; AND • Documentation of LVEF \leq 35 percent; AND • Patient is in sinus rhythm; AND • Documentation of resting heart rate \geq 70 bpm; AND • Patient is receiving maximally-tolerated doses of either bisoprolol, carvedilol, or metoprolol succinate extended release as verified by claims history. If no history of claims for a beta blocker, documentation of reason for contraindication to beta blocker therapy is required.
<p><u>Short-Acting Beta₂ Adrenergic Agonists</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least a nebulized and metered dose inhaler formulation of albuterol must be preferred. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Continue quantity limits on agents in this class. 4. For any new chemical entity in the Short-Acting Beta₂ Adrenergic Agonists class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Selected Preferred Agent (s) albuterol inhalation solution albuterol low-dose inhalation solution ProAir HFA[®] Proventil HFA[®] terbutaline tablets</p> <p>Non Preferred Agent (s) albuterol oral syrup, tablets albuterol ER tablets levalbuterol inhalation solution metaproterenol oral syrup, tablets ProAir Respiclick[®] Ventolin HFA[®] Vospire ER[®] Xopenex[®] Xopenex[®] HFA</p>

Description of Recommendation	Final Decision (s)
<p><u>Long-Acting Beta₂ Adrenergic Agents</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one unique chemical entity available in a metered dose inhaler should be preferred. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Continue quantity limits on agents in this class. 4. For any new chemical entity in the Long-Acting Beta₂ Adrenergic Agents class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Selected Preferred Agent (s) Foradil[®] Aerolizer[®]</p> <p>Non Preferred Agent (s) Arcapta[™] Neohaler[™] Brovana[®] Perforomist[™] Serevent[®] Diskus Striverdi[®] Respimat[®]</p>
<p><u>Inhaled Corticosteroids</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least three unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Continue quantity limits on agents in this class. 4. Continue to allow budesonide respules without PA for patients less than 8 years of age. 5. For any new chemical entity in the Inhaled Corticosteroid class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Selected Preferred Agent (s) Asmanex[®] Twisthaler Flovent Diskus[®] Flovent HFA[®] Pulmicort Respules[®] 0.25, 0.5 mg QVAR[®]</p> <p>Non Preferred Agent (s) Aerospan[™] Alvesco[®] Arnuity[™] Ellipta[®] Asmanex[®] HFA budesonide inhalation suspension Pulmicort Flexhaler[®] Pulmicort Respules[®] 1 mg</p>
<p><u>Beta Agonists: Combination Products</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least one unique chemical entity FDA-approved for asthma and COPD should be preferred. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Continue quantity limits on agents in this class. 4. For any new chemical entity in the Beta Agonists: Combination Products class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Selected Preferred Agent (s) Advair[®] Diskus Advair[®] HFA Dulera[®] Symbicort[®]</p> <p>Non Preferred Agent (s) Breo[®] Ellipta[®]</p>

Description of Recommendation	Final Decision (s)
<p><u>COPD Agents</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least three unique chemical entities should be preferred. At least one combination product and tiotropium should be among the preferred products. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Continue quantity limits on agents in this class. 4. For any new chemical entity in the COPD Agents class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Selected Preferred Agent (s) albuterol/ipratropium inhalation solution Atrovent[®] HFA Combivent[®] Respimat[®] ipratropium inhalation solution Spiriva Handihaler[®]</p> <p>Non Preferred Agent (s) Anoro[™] Ellipta[™] Daliresp[™] Incruse[®] Ellipta[®] Spiriva[®] Respimat[®] Tudorza[™] Pressair[™]</p>
<p><u>Leukotriene Modifiers</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent (s) based on economic evaluation; however, at least montelukast should be preferred. 2. Continue quantity limits on agents in this class based on maximum approved dose. 3. For any new chemical entity in the Leukotriene Modifiers class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Selected Preferred Agent (s) montelukast zafirlukast</p> <p>Non Preferred Agent (s) Accolate[®] Singulair[®] Zyflo[®] Zyflo CR[®]</p>
<p><u>First-Generation Antipsychotics</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation; however, at least four unique chemical entities, at least one representing an agent from each of the potency groups, should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior authorization 3. Allow continuation of therapy for non preferred single source branded products via a 90 day look back. 4. For any new chemical entity in the First-Generation Antipsychotics class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Selected Preferred Agent (s) amitriptyline/perphenazine chlorpromazine fluphenazine haloperidol loxapine Orap[®] perphenazine thioridazine thiothixene trifluoperazine</p> <p>Non Preferred Agent (s) Adasuve[®]</p>

Description of Recommendation	Final Decision (s)
<p><u>Second-Generation Antipsychotics</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation; however, at least five unique chemical entities should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior approval. 3. Continue quantity limits on agents in this class 4. Allow continuation of therapy for non preferred single source branded products via a 90 day look back. 5. For any new chemical entity in the Second-Generation Antipsychotics class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Selected Preferred Agent (s)</p> <p>Abilify[®] clozapine Fanapt[™] Latuda[®] olanzapine quetiapine risperidone Saphris[®] Seroquel XR[®] ziprasidone</p> <p>Non Preferred Agent (s)</p> <p>aripiprazole tablets Clozaril[®] FazaClo[®] Geodon[®] Invega[®] Risperdal[®] Seroquel[®] Versacloz[™] Zyprexa[®]</p>
<p><u>Second-Generation Antipsychotics Clinical Criteria</u></p> <p>Preferred Second-Generation Antipsychotics will be allowed for specific diagnoses only.</p> <p>*Non preferred Second-Generation Antipsychotics will be approved after a 2-week trial of ONE preferred Second-Generation Antipsychotic at an appropriate dose.</p> <p>** For a non-approvable diagnosis, a Second-Generation Antipsychotic may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.</p> <p>Major Depressive Disorder (MDD) Criteria:</p> <ul style="list-style-type: none"> • Second-Generation Antipsychotics will be approved for MDD as adjunct therapy ONLY. Second-Generation Antipsychotics will be approved if any ONE of the following is true: <ul style="list-style-type: none"> ○ An adequate trial (4 weeks) of at least one agent 	<p>Preferred Second-Generation Antipsychotics will be allowed for specific diagnoses only.</p> <p>*Non preferred Second-Generation Antipsychotics will be approved after a 2-week trial of ONE preferred Second-Generation Antipsychotic at an appropriate dose.</p> <p>** For a non-approvable diagnosis, a Second-Generation Antipsychotic may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.</p> <p>Major Depressive Disorder (MDD) Criteria:</p> <ul style="list-style-type: none"> • Second-Generation Antipsychotics will be approved for MDD as adjunct therapy ONLY. Second-Generation Antipsychotics will be approved if any ONE of the following is true: <ul style="list-style-type: none"> ○ An adequate trial (4 weeks) of at least one agent in two of the following classes of

<p>in two of the following classes of antidepressants (unless contraindicated or intolerant to):</p> <ul style="list-style-type: none"> ▪ Selective Serotonins Reuptake Inhibitor (SSRIs) ▪ Serotonin-Norepinephrine Reuptake Inhibitor (SNRIs) ▪ Antidepressants, Other ▪ Tricyclic antidepressants (TCAs); OR <p>○ A diagnosis of Major Depressive Disorder (MDD) with psychotic features.</p> <p>Multiple Agents Criteria: Patients who are on more than 2 Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons:</p> <ul style="list-style-type: none"> • A maximum of 2 months to allow patients to taper to dual therapy. • Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose of each agent. 	<p>antidepressants (unless contraindicated or intolerant to):</p> <ul style="list-style-type: none"> ▪ Selective Serotonins Reuptake Inhibitor (SSRIs) ▪ Serotonin-Norepinephrine Reuptake Inhibitor (SNRIs) ▪ Antidepressants, Other ▪ Tricyclic antidepressants (TCAs); OR <p>○ A diagnosis of Major Depressive Disorder (MDD) with psychotic features.</p> <p>Multiple Agents Criteria: Patients who are on more than 2 Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons:</p> <ul style="list-style-type: none"> • A maximum of 2 months to allow patients to taper to dual therapy. • Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose of each agent.
<p><u>Injectable Antipsychotics</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation. Generic formulations of first generation injectable antipsychotics should be preferred. Additionally, three unique second generation injectable antipsychotics, one of which should have a duration of action of 2 weeks or longer, should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior approval. 3. Continue quantity limits on agents in this class. 4. Allow continuation of therapy for non preferred single source branded products via a 90 day look back. 5. For any new chemical entity in the Injectable Antipsychotics class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Selected Preferred Agent (s)</p> <p>Abilify Maintena™ fluphenazine decanoate Geodon® haloperidol decanoate haloperidol lactate Invega® Sustenna® olanzapine Risperdal® Consta®</p> <p>Non Preferred Agent (s)</p> <p>Haldol® Decanoate Haldol® lactate Invega Trinza™ Zyprexa® Zyprexa® Relprevv</p>

Description of Recommendation	Final Decision (s)
<p><u>Injectable Antipsychotics Clinical Criteria</u> Preferred Injectable Antipsychotics will be allowed for specific diagnoses only.</p> <p>*Non preferred Injectable Antipsychotics will be approved after a 2-week trial of ONE preferred Antipsychotic (oral or parenteral) at an appropriate dose.</p> <p>**For a non-approvable diagnosis, an injectable antipsychotic may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.</p> <p>Multiple Therapy Criteria: Patients who are on more than two Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons:</p> <ul style="list-style-type: none"> • A maximum of 2 months to allow patients to taper to dual therapy. • Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose if each agent. 	<p>Preferred Injectable Antipsychotics will be allowed for specific diagnoses only.</p> <p>*Non preferred Injectable Antipsychotics will be approved after a 2-week trial of ONE preferred Antipsychotic (oral or parenteral) at an appropriate dose.</p> <p>**For a non-approvable diagnosis, an injectable antipsychotic may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.</p> <p>Multiple Therapy Criteria: Patients who are on more than two Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons:</p> <ul style="list-style-type: none"> • A maximum of 2 months to allow patients to taper to dual therapy. • Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose if each agent.
<p><u>Second-Generation Antipsychotic and SSRI Combination</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation. 2. Agents not selected as preferred will be considered non preferred and require prior approval. 3. Continue quantity limits on agents in this class. 4. Allow continuation of therapy for non preferred single source branded products via a 90 day look back. 5. For any new chemical entity in the Second-Generation Antipsychotic and SSRI Combination class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Selected Preferred Agent (s) Symbyax®</p> <p>Non Preferred Agent (s) olanzapine/fluoxetine</p>

Description of Recommendation	Final Decision (s)
<p><u>Second-Generation Antipsychotic and SSRI Combination Clinical Criteria</u></p> <p>Olanzapine/fluoxetine will be approved if ONE of the following is true:</p> <ul style="list-style-type: none"> • Diagnosis of depressive episodes associated with bipolar disorder after trial and failure of ONE of the following: <ul style="list-style-type: none"> ○ Lithium; OR ○ Lamotrigine; OR ○ Bupropion; OR ○ Paroxetine. • Diagnosis of treatment-resistant depression after trial and failure of one agent from THREE of the following classes of medications: <ul style="list-style-type: none"> ○ SSRI; ○ SNRI; ○ New Generation Antidepressant; ○ Tricyclic Antidepressant; ○ MAOI. <p>** For a non-approvable diagnosis, olanzapine/fluoxetine may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.</p> <p>Multiple Therapy Criteria:</p> <ul style="list-style-type: none"> • Patients who are on more than 2 Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons: <ul style="list-style-type: none"> ○ A maximum of 2 months to allow patients to taper to dual therapy. ○ Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose of each agent. 	<p>Olanzapine/fluoxetine will be approved if ONE of the following is true:</p> <ul style="list-style-type: none"> • Diagnosis of depressive episodes associated with bipolar disorder after trial and failure of ONE of the following: <ul style="list-style-type: none"> ○ Lithium; OR ○ Lamotrigine; OR ○ Bupropion; OR ○ Paroxetine. • Diagnosis of treatment-resistant depression after trial and failure of one agent from THREE of the following classes of medications: <ul style="list-style-type: none"> ○ SSRI; ○ SNRI; ○ New Generation Antidepressant; ○ Tricyclic Antidepressant; ○ MAOI. <p>** For a non-approvable diagnosis, olanzapine/fluoxetine may be approved if the prescriber can provide documented clinical evidence (peer reviewed literature or multiple case studies) supporting the use of the requested medication for the requested indication.</p> <p>Multiple Therapy Criteria:</p> <ul style="list-style-type: none"> • Patients who are on more than 2 Second-Generation Antipsychotic agents will require PA. Approval will be granted for the following reasons: <ul style="list-style-type: none"> ○ A maximum of 2 months to allow patients to taper to dual therapy. ○ Additional agents may be added to existing dual therapy after a 2-week trial at the maximum tolerated dose of each agent.

Description of Recommendation	Final Decision (s)
<p><u>Stimulants and Related Agents</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based on economic evaluation; however, at least one short-acting, one intermediate-acting and one long-acting formulation of methylphenidate, one short-acting and one long-acting formulation of an amphetamine derivative, one alpha2 agonist and atomoxetine should be preferred. 2. Agents not selected as preferred will be considered non preferred and require prior approval. 3. Continue current quantity limits. 4. Allow continuation of therapy for non preferred single-source branded products via a 90 day look back. 5. For any new chemical entity in the Stimulants and Related Agents class, require a PA until reviewed by the P&T Advisory Committee. 	<p>Selected Preferred Agent (s)</p> <p>Adderall XR[®] dexamethylphenidate IR dextroamphetamine IR dextroamphetamine ER Focalin XRTM guanfacine ER Metadate CD[®] Metadate ER[®] Methylin[®] chewable tablets methylphenidate IR tablets, capsules methylphenidate ER/SA/SR methylphenidate ER OROS mixed amphetamine salts IR QuillivantTM XR Strattera[®] VyvanseTM</p> <p>Non Preferred Agent (s)</p> <p>Adderall[®] Aptensio XR[®] clonidine ER Concerta[®] DaytranaTM Desoxyn[®] Dexedrine[®] dexamethylphenidate ER dextroamphetamine solution EvekeoTM FocalinTM IntunivTM KapvayTM methamphetamine Methylin[®] solution methylphenidate (Generic for Metadate CD[®]) methylphenidate chewable (Generic for Methylin[®] chewable tablets) methylphenidate LA (Generic for Ritalin LA[®]) methylphenidate solution mixed amphetamine salts ER ProcentraTM Ritalin[®] Ritalin LA[®] ZenzediTM</p>

Description of Recommendation	Final Decision (s)
<p><u>Stimulants and Related Agents Clinical Criteria</u> Stimulants and Related Agents will be approved for specific diagnoses only.</p> <p>**Agents may be approved for other diagnosis via the prior authorization process based on a review of the current literature by a clinical pharmacist.</p> <p>Non preferred non-solid dosage forms will be approved if either of the following criteria is met:</p> <ul style="list-style-type: none"> • Trial and failure of two preferred products, one of which must be the same chemical as the requested medication; OR • Inability to swallow/tolerate PO/whole tablets/capsules <p>Therapeutic Duplication Prior authorization will be required for more than one long-acting or more than one short-acting stimulant at a time.</p>	<p>Stimulants and Related Agents will be approved for specific diagnoses only.</p> <p>**Agents may be approved for other diagnosis via the prior authorization process based on a review of the current literature by a clinical pharmacist.</p> <p>Non preferred non-solid dosage forms will be approved if either of the following criteria is met:</p> <ul style="list-style-type: none"> • Trial and failure of two preferred products, one of which must be the same chemical as the requested medication; OR • Inability to swallow/tolerate PO/whole tablets/capsules <p>Therapeutic Duplication Prior authorization will be required for more than one long-acting or more than one short-acting stimulant at a time.</p>
<p><u>Narcolepsy Agents</u></p> <ol style="list-style-type: none"> 1. DMS to select preferred agent(s) based upon economic evaluation; however, at least one unique chemical entity should be preferred. 2. Agents not selected as preferred will be considered non-preferred and will require Prior Authorization. 3. Continue current quantity limits on agents in this class. 4. Any new chemical entity in the Narcolepsy Agents class should require a PA until reviewed by the P&T Advisory Committee. 	<p><u>Selected Preferred Agent (s)</u> Provigil[®]</p> <p><u>Non Preferred Agent (s)</u> modafinil Nuvigil[®] Xyrem[®]</p>
<p><u>Narcolepsy Agents Clinical Criteria</u> Narcolepsy Agents will be approved based on their FDA-approved indications for the following diagnoses:</p> <ul style="list-style-type: none"> • Obstructive sleep apnea / hypopnea syndrome; OR • Shift work sleep disorder; OR • Narcolepsy; OR • Cataplexy Associated with Narcolepsy. 	<p>Narcolepsy Agents will be approved based on their FDA-approved indications for the following diagnoses:</p> <ul style="list-style-type: none"> • Obstructive sleep apnea / hypopnea syndrome; OR • Shift work sleep disorder; OR • Narcolepsy; OR • Cataplexy Associated with Narcolepsy.